Developer docs
API playgroundTry for free, no card

Search company profiles

Bexorg

Full company profile

uuid000rwh2

Namestring
Bexorg
Legal namestring
Bexorg, Inc.
Websiteurl
bexorg.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Bexorg is a private CNS drug discovery platform company founded in 2021 and spun out of Yale University research by Drs. Zvonimir Vrselja and Nenad Sestan. The company's core technology, BrainEx, is a proprietary whole-brain perfusion system that restores molecular activity in postmortem donated human brains, creating a uniquely translational model for testing therapeutics directly in physiologically intact human brain tissue. BrainEx is paired with an integrated AI stack (XO Digital / NeuroScale / NeuroLens) that ingests molecular, transcriptomic, proteomic, and metabolic data from each experiment to train predictive models, forming a closed-loop system of in-silico prediction and wet-lab validation.

The platform addresses the structural 95%+ CNS clinical trial failure rate by enabling pharmaceutical and biotech partners to test drug candidates (small molecules, biologics, viral vectors, LNPs) in human brain tissue across disease-relevant states including Alzheimer's and Parkinson's, generating target engagement, pharmacokinetic/pharmacodynamic, and biomarker data prior to clinical entry. Bexorg operates a B2B enterprise model with strategic research collaborations; its anchor customer Biohaven has used approximately 130 brains to advance two preclinical programs, and the company has additional collaborations with the University of Oxford / UK Medical Research Council and The Michael J. Fox Foundation.

Bexorg is headquartered in New Haven, Connecticut near Yale, with a secondary office in San Francisco, and operates a new robotic lab capable of processing up to 1,600 brains per year. As of January 2026 the company has 41 employees and $42.5 million in total funding, including a $23 million Series A led by Engine Ventures in October 2025. Revenue is generated through professional services and recurring partnership arrangements with enterprise pharma and biotech clients, with pricing not publicly disclosed.

Short descriptiontext

Bexorg is a Yale-spinout CNS drug discovery platform that combines proprietary whole-human brain perfusion (BrainEx) with an AI engine (XO Digital/NeuroLens) to test therapeutics directly in human brain tissue, serving pharmaceutical and biotech partners seeking to reduce the 95%+ CNS clinical trial failure rate.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew Haven, United States
HQ citystring
New Haven
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS drug discovery, whole-brain perfusion, AI neuroscience platform, preclinical drug testing, neurodegenerative disease research
Industry2 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
CNS Drug Discovery Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Research Collaboration Services
TypeProfessional Services
Description

Bexorg generates revenue through multi-program research collaborations with pharmaceutical companies. The company provides its whole-brain discovery platform to demonstrate target engagement, generate biomarkers, pharmacokinetic/pharmacodynamic data, and mechanistic insights to support preclinical development programs. Revenue comes from service fees for experiments and data generation.

bexorg.com
2Strategic Partnership Programs
TypeSubscription Recurring
Description

Collaborative partnerships where Bexorg delivers insights from drug testing on whole human brains, including analysis of pharmacokinetics, pharmacodynamics, and mechanism of action. May include co-development arrangements and milestone payments.

bexorg.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1BrainEx
Description

The proprietary whole-brain perfusion platform that restores molecular activity in donated whole-human brains, creating a translational model for clinically predictive data and drug discovery.

bexorg.com
+2 more records
Core offering1 text field

Bexorg operates the Brainex Platform, an integrated drug discovery system that combines the BrainEx whole-brain perfusion technology—capable of restoring molecular activity in postmortem human brains—with AI engines (NeuroScale/NeuroLens/XO Digital) that translate experimental data into predictive models. The company sells research collaboration services to pharmaceutical and biotech partners, enabling them to test therapeutics directly in physiologically intact human brain tissue to generate pharmacokinetic, pharmacodynamic, and biomarker data for CNS drug development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 95% CNS clinical trial failure rate reduced through human brain testing
+3 more records
Product overview1 text field

Bexorg offers an integrated drug discovery platform called the Brainex Platform, which combines the BrainEx whole-brain perfusion system with NeuroScale experimental capabilities and the XO Digital AI engine. BrainEx restores molecular activity in postmortem human brains for direct drug testing, NeuroScale captures dynamic molecular data in real time, and XO Digital creates a closed-loop AI system that learns from experiments to generate predictive models. Together, these components aim to address the 95%+ CNS clinical trial failure rate by generating human-relevant data instead of relying on animal or cell models.

Product and service3 records
1Brainex Platform
CategoryCNS Drug Discovery Platform
Description

Integrated drug discovery platform that combines whole-brain perfusion experimentation with AI-driven predictive modeling, designed to generate clinically predictive human CNS data for pharmaceutical and biotech partners developing therapies for neurodegenerative and other neurological diseases.

2BrainEx
CategoryExperimental Technology Platform
Description

Proprietary whole-brain perfusion platform that restores molecular activity in donated postmortem human brains, enabling systematic delivery of small molecules, biologics, viral vectors, and LNPs through the competent vascular system and blood-brain barrier for direct drug testing in physiologically intact human brain tissue.

3Research Collaboration Services
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1The Michael J. Fox Foundation for Parkinson's Research
Strategic tierCoreTypeOthersAnnounced on2026-01-28
Description

Research grant awarded through the Targets to Therapies Initiative to identify translational biomarkers for TRPML1-targeted Parkinson's disease therapies. Bexorg leverages its postmortem whole-human brain platform to identify biomarkers that track drug activity in human brain tissue donated by people who lived with Parkinson's disease.

markets.businessinsider.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-10
Description

Multi-program research collaboration to identify, de-risk, and advance next-generation therapies for CNS disorders. Bexorg's whole-brain discovery platform is used to demonstrate target engagement in relevant cell types and tissues and generate novel biomarkers, pharmacokinetic and pharmacodynamic relationships, and other mechanistic data to support two preclinical development programs at Biohaven.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Partnership with University of Oxford and UK Medical Research Council as part of collaborative effort to advance translational gene therapy development for neurological diseases.

Strategic tierCoreTypeOthers
Description

Organ procurement organization that provides high-quality, ethically sourced human biological materials for research. Supplies postmortem whole brains to Bexorg for drug testing.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning. Directly comparable to Bexorg in using AI/automation to generate proprietary experimental datasets and partner with pharma, though focused on image-based cellular assays rather than whole-brain tissue.

TypeDirect peer
Description

Machine-learning-enabled drug discovery platform that combines engineered human cell models with predictive models. Comparable as an AI-first biotech generating proprietary human-relevant datasets for pharma partnerships, especially in CNS and metabolic disease.

TypeDirect peer
Description

AI-driven small molecule discovery company using structure-based deep learning to partner with pharma. Comparable as an AI-platform business that sells discovery collaborations to large pharma rather than developing assets solo, though Bexorg's wet-lab data engine is uniquely physical.

TypeBroad incumbent
Description

Largest contract research organization providing preclinical and discovery services to pharma, including CNS animal models. Comparable as a high-touch preclinical services partner to pharma but lacks Bexorg's whole-human-brain and AI capabilities.

TypeDirect peer
Description

End-to-end AI drug discovery company combining generative chemistry, target identification, and clinical development. Comparable as an AI drug discovery platform with pharma partnerships and an in-house pipeline, and a leading indicator for the AI-platform biotech model Bexorg aspires to.

TypeEmerging player
Description

AI-native drug discovery startup founded in 2023 with over $1B in funding, applying foundation models to biology. Comparable as a well-capitalized AI-bio platform with a similar model of building proprietary biological data assets to power drug discovery partnerships.

7Organoid Therapeutics
TypeEmerging player
Description

Emerging CNS-focused biotech using patient-derived organoid models for drug discovery. Comparable as an alternative translational CNS platform pursuing pharma collaborations, though using organoids rather than whole-brain perfusion and competing for the same partner wallet.

TypeEmerging player
Description

Organ-on-chip platform providing human-relevant in vitro models for pharma R&D. Comparable as a higher-fidelity alternative to animal models in CNS and other tissues, and a potential substitute buyer-side option for Bexorg's pharma customers.

TypeOthers
Description

CNS-focused pharmaceutical company and Bexorg's flagship partner. Included as a customer/strategic counterpart rather than a competitor; provides insight into how Bexorg's anchor customer evaluates and consumes external CNS discovery platforms.

TypeOthers
Description

Clinical-stage CNS biotech developing therapeutics for neurodegenerative diseases. Comparable as a potential customer archetype for Bexorg's platform (a CNS biotech with multiple programs needing human-brain validation), rather than a direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bexorg

CNS Drug Discovery Platformbexorg.com

Bexorg is a Yale-spinout CNS drug discovery platform that combines proprietary whole-human brain perfusion (BrainEx) with an AI engine (XO Digital/NeuroLens) to test therapeutics directly in human brain tissue, serving pharmaceutical and biotech partners seeking to reduce the 95%+ CNS clinical trial failure rate.

What Bexorg does

Bexorg is a private CNS drug discovery platform company founded in 2021 and spun out of Yale University research by Drs. Zvonimir Vrselja and Nenad Sestan. The company's core technology, BrainEx, is a proprietary whole-brain perfusion system that restores molecular activity in postmortem donated human brains, creating a uniquely translational model for testing therapeutics directly in physiologically intact human brain tissue. BrainEx is paired with an integrated AI stack (XO Digital / NeuroScale / NeuroLens) that ingests molecular, transcriptomic, proteomic, and metabolic data from each experiment to train predictive models, forming a closed-loop system of in-silico prediction and wet-lab validation.

The platform addresses the structural 95%+ CNS clinical trial failure rate by enabling pharmaceutical and biotech partners to test drug candidates (small molecules, biologics, viral vectors, LNPs) in human brain tissue across disease-relevant states including Alzheimer's and Parkinson's, generating target engagement, pharmacokinetic/pharmacodynamic, and biomarker data prior to clinical entry. Bexorg operates a B2B enterprise model with strategic research collaborations; its anchor customer Biohaven has used approximately 130 brains to advance two preclinical programs, and the company has additional collaborations with the University of Oxford / UK Medical Research Council and The Michael J. Fox Foundation.

Bexorg is headquartered in New Haven, Connecticut near Yale, with a secondary office in San Francisco, and operates a new robotic lab capable of processing up to 1,600 brains per year. As of January 2026 the company has 41 employees and $42.5 million in total funding, including a $23 million Series A led by Engine Ventures in October 2025. Revenue is generated through professional services and recurring partnership arrangements with enterprise pharma and biotech clients, with pricing not publicly disclosed.

Bexorg firmographics

Firmographics
Name
Bexorg
Legal name
Bexorg, Inc.
Website
https://bexorg.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Bexorg is a Yale-spinout CNS drug discovery platform that combines proprietary whole-human brain perfusion (BrainEx) with an AI engine (XO Digital/NeuroLens) to test therapeutics directly in human brain tissue, serving pharmaceutical and biotech partners seeking to reduce the 95%+ CNS clinical trial failure rate.
Ownership category
akta.pro rank

Bexorg industry classification

Industry
Product category
CNS Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • CNS drug discovery
  • Whole-brain perfusion
  • AI neuroscience platform
  • Preclinical drug testing
  • Neurodegenerative disease research

Where Bexorg is headquartered

Location

Headquarters

HQ city
New Haven
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Bexorg business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Research Collaboration Services: Bexorg generates revenue through multi-program research collaborations with pharmaceutical companies. The company provides its whole-brain discovery platform to demonstrate target engagement, generate biomarkers, pharmacokinetic/pharmacodynamic data, and mechanistic insights to support preclinical development programs. Revenue comes from service fees for experiments and data generation.
  2. Strategic Partnership Programs: Collaborative partnerships where Bexorg delivers insights from drug testing on whole human brains, including analysis of pharmacokinetics, pharmacodynamics, and mechanism of action. May include co-development arrangements and milestone payments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Bexorg product offering

Product offering

Core offering

Bexorg operates the Brainex Platform, an integrated drug discovery system that combines the BrainEx whole-brain perfusion technology—capable of restoring molecular activity in postmortem human brains—with AI engines (NeuroScale/NeuroLens/XO Digital) that translate experimental data into predictive models. The company sells research collaboration services to pharmaceutical and biotech partners, enabling them to test therapeutics directly in physiologically intact human brain tissue to generate pharmacokinetic, pharmacodynamic, and biomarker data for CNS drug development.

Product overview

Bexorg offers an integrated drug discovery platform called the Brainex Platform, which combines the BrainEx whole-brain perfusion system with NeuroScale experimental capabilities and the XO Digital AI engine. BrainEx restores molecular activity in postmortem human brains for direct drug testing, NeuroScale captures dynamic molecular data in real time, and XO Digital creates a closed-loop AI system that learns from experiments to generate predictive models. Together, these components aim to address the 95%+ CNS clinical trial failure rate by generating human-relevant data instead of relying on animal or cell models.

Differentiator

Problem solved

Functional benefit

Brands

  • BrainEx: The proprietary whole-brain perfusion platform that restores molecular activity in donated whole-human brains, creating a translational model for clinically predictive data and drug discovery.
  • XO Digital (NeuroScale)
  • NeuroLens

Products and services

  • Brainex Platform Integrated drug discovery platform that combines whole-brain perfusion experimentation with AI-driven predictive modeling, designed to generate clinically predictive human CNS data for pharmaceutical and biotech partners developing therapies for neurodegenerative and other neurological diseases.
  • BrainEx Proprietary whole-brain perfusion platform that restores molecular activity in donated postmortem human brains, enabling systematic delivery of small molecules, biologics, viral vectors, and LNPs through the competent vascular system and blood-brain barrier for direct drug testing in physiologically intact human brain tissue.
  • Research Collaboration Services

Quantifiable outcome

  • Over 95% CNS clinical trial failure rate reduced through human brain testing
  • +3 more outcomes

Companies that use Bexorg

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Bexorg technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Bexorg partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and strategic.

  • The Michael J. Fox Foundation for Parkinson's ResearchcoreOthers · 28 January 2026Research grant awarded through the Targets to Therapies Initiative to identify translational biomarkers for TRPML1-targeted Parkinson's disease therapies. Bexorg leverages its postmortem whole-human brain platform to identify biomarkers that track drug activity in human brain tissue donated by people who lived with Parkinson's disease.
  • BiohavencoreStrategic or Co-development Partner · 10 June 2025Multi-program research collaboration to identify, de-risk, and advance next-generation therapies for CNS disorders. Bexorg's whole-brain discovery platform is used to demonstrate target engagement in relevant cell types and tissues and generate novel biomarkers, pharmacokinetic and pharmacodynamic relationships, and other mechanistic data to support two preclinical development programs at Biohaven.
  • University of OxfordstrategicStrategic or Co-development Partner · 1 January 2024Partnership with University of Oxford and UK Medical Research Council as part of collaborative effort to advance translational gene therapy development for neurological diseases.
  • LifeNet HealthcoreOthersOrgan procurement organization that provides high-quality, ethically sourced human biological materials for research. Supplies postmortem whole brains to Bexorg for drug testing.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Bexorg competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Directly comparable to Bexorg in using AI/automation to generate proprietary experimental datasets and partner with pharma, though focused on image-based cellular assays rather than whole-brain tissue.
  • Insitro: Machine-learning-enabled drug discovery platform that combines engineered human cell models with predictive models. Comparable as an AI-first biotech generating proprietary human-relevant datasets for pharma partnerships, especially in CNS and metabolic disease.
  • Atomwise: AI-driven small molecule discovery company using structure-based deep learning to partner with pharma. Comparable as an AI-platform business that sells discovery collaborations to large pharma rather than developing assets solo, though Bexorg's wet-lab data engine is uniquely physical.
  • InSilico Medicine: End-to-end AI drug discovery company combining generative chemistry, target identification, and clinical development. Comparable as an AI drug discovery platform with pharma partnerships and an in-house pipeline, and a leading indicator for the AI-platform biotech model Bexorg aspires to.

Broad incumbents

  • Charles River Laboratories: Largest contract research organization providing preclinical and discovery services to pharma, including CNS animal models. Comparable as a high-touch preclinical services partner to pharma but lacks Bexorg's whole-human-brain and AI capabilities.

Emerging players

  • Xaira Therapeutics: AI-native drug discovery startup founded in 2023 with over $1B in funding, applying foundation models to biology. Comparable as a well-capitalized AI-bio platform with a similar model of building proprietary biological data assets to power drug discovery partnerships.
  • Organoid Therapeutics: Emerging CNS-focused biotech using patient-derived organoid models for drug discovery. Comparable as an alternative translational CNS platform pursuing pharma collaborations, though using organoids rather than whole-brain perfusion and competing for the same partner wallet.
  • Emulate: Organ-on-chip platform providing human-relevant in vitro models for pharma R&D. Comparable as a higher-fidelity alternative to animal models in CNS and other tissues, and a potential substitute buyer-side option for Bexorg's pharma customers.

Others

  • Biohaven (now part of Pfizer): CNS-focused pharmaceutical company and Bexorg's flagship partner. Included as a customer/strategic counterpart rather than a competitor; provides insight into how Bexorg's anchor customer evaluates and consumes external CNS discovery platforms.
  • Denali Therapeutics: Clinical-stage CNS biotech developing therapeutics for neurodegenerative diseases. Comparable as a potential customer archetype for Bexorg's platform (a CNS biotech with multiple programs needing human-brain validation), rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Bexorg social profiles

Digital presence

Bexorg financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bexorg leadership team

Management profile

Number of profiles

Profiles6 records

Bexorg funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bexorg M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bexorg

What does Bexorg do?

Bexorg operates the Brainex Platform, an integrated drug discovery system that combines the BrainEx whole-brain perfusion technology—capable of restoring molecular activity in postmortem human brains—with AI engines (NeuroScale/NeuroLens/XO Digital) that translate experimental data into predictive models. The company sells research collaboration services to pharmaceutical and biotech partners, enabling them to test therapeutics directly in physiologically intact human brain tissue to generate pharmacokinetic, pharmacodynamic, and biomarker data for CNS drug development.

Is Bexorg a public or private company?

Bexorg is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bexorg founded?

Bexorg was founded in 2021. It employs 11 to 50 people.

Where is Bexorg based?

Bexorg is headquartered in New Haven, United States, in the North America region.

How does Bexorg make money?

Two revenue lines are on record. Research Collaboration Services are the primary driver. The others are strategic Partnership Programs.

Who are Bexorg's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Atomwise and InSilico Medicine. Charles River Laboratories is listed as a broad incumbent. Emerging players are Xaira Therapeutics, Organoid Therapeutics and Emulate. Others are Biohaven (now part of Pfizer) and Denali Therapeutics.

Does Bexorg have an API?

No public API is recorded for Bexorg.

What industry is Bexorg in?

Bexorg's product category is CNS Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialBexorg Appoints Mikael Dolsten, M.D., Ph.D., As Chairman Of Its Board Of DirectorsBexorg appointed Mikael Dolsten, former Pfizer CSO, as chairman of its board, succeeding Zvonimir Vrselja, who remains CEO. Jon Faiz Kayyem is retiring from the board. Dolsten will help advance Bexorg's BrainEx platform and build a drug portfolio.Longevity.TechnologyDonated human brains may soon be studied for two weeksBexorg received up to $28.3 million from ARPA-H to extend its BrainEx platform's perfusion of donated human brains from 24 hours to two weeks over a 36-month project. The company aims to validate long-term drug responses and biomarkers, with Alzheimer's disease as a target. The award is conditional on demonstrating two-week perfusion and matching results to clinical outcomes.Longevity.TechnologyBexorg awarded up to $28.3m from ARPA-HBexorg received up to $28.3 million from ARPA-H to extend its BrainEx perfusion platform from 24 hours to two weeks. The project aims to enable longitudinal human brain pharmacology studies, including repeated dosing and sustained drug exposure. The company also cites prior validation with Biohaven's BHV-8100 in a Phase 1 trial.STATUp and down the ladder: The latest comings and goingsBexorg has appointed Bruce Car as its new chief scientific officer. This move highlights Bexorg's efforts to enhance its leadership in the pharmaceutical sector. The article also invites readers to share updates about personnel changes in the industry.Endpoints NewsZealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hireSilvia Luque was named head of US marketing at Zealand Pharma after 13 years at Eli Lilly, according to a LinkedIn announcement. Separately, Bexorg hired a chief scientific officer from Biohaven. Both moves represent executive talent acquisitions in the biotech and pharmaceutical sectors.BioSpaceBexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business OfficerBexorg appointed Bruce Car as Chief Scientific Officer and Michael Fenn as Chief Business Officer. Car brings over 30 years of drug discovery experience, and Fenn leads business development and asset strategy. The appointments support Bexorg's platform to characterize human brain pharmacology before first-in-human dosing, with BHV-8100 in Phase 1.The Cool DownStartup extracts human brains hours after death and keeps them alive for 24 hours to test drugsBexorg extracts human brains within hours of death and preserves them for 24 hours on its BrainEX platform to test drugs. The company plans to process up to 1,600 brains annually, with Biohaven having used 130 in Parkinson's research. The system aims to improve drug testing for neurodegenerative diseases.VICEWhy This Biotech Company Is Keeping Bodiless Human Brains Alive in a LabBexorg's BrainEx platform keeps donated human brains alive for about 24 hours using a life-support system, allowing researchers to test drugs on real human tissue. The company has studied over 700 brains, and Biohaven has used 130 to evaluate experimental therapies.FuturismStartup Testing Drugs on Freshly Extracted Human Brains That Are Kept On Life SupportBiotech startup Bexorg is extracting human brains hours after death and keeping them alive on its proprietary BrainEX life support machines to enable drug testing, with the extracted brains remaining functional for up to 24 hours before being sliced into pieces for analysis. The company, which previously demonstrated this capability with pig brains kept alive for 36 hours, plans to process up to 1,600 brains per year using robotic arms. Pharmaceutical firm Biohaven has already used 130 of these brains to test drugs including potential Parkinson's treatments and plans to launch a clinical trial based on data gathered from these experiments.Hartford Business JournalFollowing $23M capital raise, brain research company Bexorg opens expanded New Haven HQBexorg, a Yale spin-off, opened an expanded New Haven headquarters after a $23 million Series A round, doubling its whole-brain testing capacity. The company is evaluating eight drug candidates for neurodegenerative diseases and expects data from 700 brains by year-end.